SOPHIA ANTIPOLIS, FRANCE--(Marketwire - November 28, 2011) -
NicOx: Patient recruitment completed by Bausch + Lomb in glaucoma study
NicOx S.A. (NYSE Euronext Paris: COX) today announced that the ongoing
study of BOL-303259-X, conducted by its partner Bausch + Lomb, has
recruitment. Bausch + Lomb anticipates that the study will be completed
end of December 2011, with preliminary results expected in the first
BOL-303259- is an NO-donating prostaglandin F2-alpha analog which is
lower intraocular pressure (IOP) through a dual mechanism of action. The
study is intended to identify the most effective dose of BOL-
administered in the evening to patients with open-angle glaucoma or
hypertension, for the reduction of IOP.
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
on the research, development and future commercialization of drug
NicOx is applying its proprietary nitric oxide-donating R&D platform to
an internal portfolio of New Molecular Entities (NMEs) for the
treatment of inflammatory, cardio-metabolic and ophthalmological diseases.
The Company's pipeline includes several nitric oxide-donating NMEs, which
development internally and with partners, who include Merck (known
outside the United States and Canada), Bausch + Lomb, and Ferrer.
NicOx S.A. is headquartered in France and is listed on Euronext
(Compartment B: Mid Caps).
This press release contains certain forward-looking statements.
Company believes its expectations are based on reasonable assumptions,
forward-looking statements are subject to numerous risks and
which could cause actual results to differ materially from those
the forward-looking statements.
Risks factors which are likely to have a material effect on NicOx's
presented in the 4(th) chapter of the « Document de
référence, rapport financier
annuel et rapport de gestion 2010 » filed with the French
Autorité des Marchés
Financiers (AMF) on February 25, 2011 and available on NicOx's
(www.nicox.com) and on the AMF's website (www.amf-france.org).
NICOX: Patient recruitment completed by Bausch + Lomb in glaucoma study:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE